--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

 
EXHIBIT 10.2
WAFERGEN BIO-SYSTEMS, INC.
 
PUT AGREEMENT
 
    THIS PUT AGREEMENT (this “Agreement”) is entered into as of May 28, 2008, by
and among WaferGen Bio-systems, Inc., a Nevada corporation (“WaferGen US”), and
the
purchasers (the “WaferGen Malaysian Investors” or “Holders”) of the Series A
Redeemable
Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd. (formerly
known as
Global Dupleks Sdn. Bhd.), a Malaysian corporation (the “Company”) (“Series A
Shares”)
pursuant to that certain Share Subscription and Shareholders Agreement dated as
of the date
hereof among WaferGen US, the WaferGen Malaysian Investors and the Company (the
“Purchase Agreement”). Any term not defined herein shall have the meaning
ascribed to such
term in the Purchase Agreement.
 
RECITALS
    
    A.    WHEREAS, the WaferGen Malaysian Investors have entered into the
Purchase
Agreement for the purchase of and subscription for certain Series A Shares of
the Company.
    
    B.    WHEREAS, in order to induce the WaferGen Malaysian Investors to enter
into
the Purchase Agreement, WaferGen US has agreed to grant to each WaferGen
Malaysian
Investor an option to put (the “Put Right”) to WaferGen US the Series A Shares
held by such
WaferGen Malaysian Investor, whereby the Series A Shares held by such WaferGen
Malaysian
Investor will be exchanged for shares of Common Stock of WaferGen US on the
terms set forth
below.
    
    C.    WHEREAS, certain capitalized terms used in this Agreement are defined
in
Section 2.12 hereof.
 
    NOW, THEREFORE, in consideration of the mutual promises, representations,
warranties, covenants and conditions set forth in this Agreement, the parties
mutually agree as
follows:
 
AGREEMENT
 
SECTION 1
PUT RIGHT
 
    1.1    Put Right. Upon receipt by WaferGen US of a written request from a
Holder of
Holder’s desire to exercise the Holder’s Put Right (a “Holder’s Put Notice”),
then all, but not
less than all, of such Holder’s Series A Shares shall be exchanged as described
in Section 1.2
below (the “Exchange”). For the avoidance of doubt, each Holder shall have the
right to
exercise such Put Right individually. After delivery of such Holder’s Put
Notice, the Holder
shall deliver all of such Holder’s share certificates and duly executed share
transfer forms with
respect to such Series A Shares to the Secretary of WaferGen US (or to his/her
order) as
promptly as practicable (but in no event more than 30 days after the date
thereof) and take any
other actions reasonably required to effectuate the transfer of all such
Holder’s Series A Shares
to WaferGen US. WaferGen US may nominate its nominee(s) to accept the transfer
of the Series
 
1

--------------------------------------------------------------------------------

 
A Shares. WaferGen US shall be required to comply with the requirements of this
paragraph
until the fifth anniversary of the date of this Agreement, but may in its sole
discretion comply
with provisions of this paragraph after such date.
 
    1.2    The Exchange; No Fractional Shares. Upon the occurrence of an
Exchange, each
of the Holder’s Series A Shares subject to such Holder’s Put Notice shall be
converted into the
right to receive that number of Exchange Securities equal to the U.S. dollar
equivalent of the
original purchase or subscription price per share paid for each such Holder’s
Series A Share
(with such conversion to U.S. dollars being calculated as of the date of
purchase) pursuant to the
Purchase Agreement, divided by the Exchange Price1 (in each case as adjusted for
stock splits,
recapitalization, combinations and similar transactions). All Exchange
Securities shall be
aggregated and issued to such Holder, except that no fractional shares of
Exchange Securities
shall be issued upon the occurrence of an Exchange. If, after the aforementioned
aggregation,
the conversion would result in the issuance of any fractional share, WaferGen US
shall, in lieu of
issuing any fractional share, pay cash equal to the product of such fraction
multiplied by the per
share fair market value of the Exchange Securities (as determined in good faith
by the Board of
Directors of WaferGen US). Subject to the delivery by the Holder of its share
certificates and
other documents to WaferGen US as required hereby, upon the occurrence of the
Exchange,
WaferGen US shall as soon as practicable (but in no event more than 30 days
after the date of the
Exchange) issue to such Holder share certificates representing the Exchange
Securities.
 
    1.3    Rights After Exchange. From and after the applicable Exchange, all
rights of the
Holder with respect to the exchanged Holder’s Series A Shares shall cease with
respect to such
shares (except the right to receive the Exchange Securities, and any cash
payment for fractional
shares, without interest upon surrender of their certificate or certificates),
and such shares shall
be owned legally and beneficially by WaferGen US for all purposes and will be
transferred to
WaferGen US on the books and records of the Company.
 
    1.4    Rights After Conversion. If at any time any or all of Holder’s Series
A Shares are
converted into Ordinary Shares of the Company for any reason, such Holder’s Put
Right
pursuant to this Agreement with respect to all of such Holder’s Series A Shares
shall terminate
and expire in its entirety upon such conversion, and such Holder shall have not
have any Put
Right with respect to any Ordinary Shares held by such Holder.
 
SECTION 2
MISCELLANEOUS
 
    2.1    Governing Law. This Agreement and all acts and transactions pursuant
hereto
and the rights and obligations of the parties hereto shall be governed,
construed and interpreted
in accordance with the laws of the State of California in the United States of
America, without
giving effect to the choice of law provisions thereof.
 
    2.2    Arbitration. The parties agree that any and all disputes, claims or
controversies
arising out of or relating to this Agreement that are not resolved by their
mutual agreement shall
be submitted to final and binding arbitration in San Francisco, California
before JAMS, or its
 
2

--------------------------------------------------------------------------------

 
successor, pursuant to the United States Arbitration Act, 9 U.S.C. Sec. 1 et
seq. Any party may
commence the arbitration process called for in this Agreement by filing a
written demand for
arbitration with JAMS, with a copy to the other party. The arbitration will be
conducted in
accordance with the provisions of JAMS’ Streamlined Arbitration Rules and
Procedures in effect
at the time of filing of the demand for arbitration. The parties will cooperate
with JAMS and
with one another in selecting an arbitrator from JAMS’ panel of neutrals, and in
scheduling the
arbitration proceedings. The parties covenant that they will participate in the
arbitration in good
faith, and that they will share equally in its costs. The provisions of this
Section 2.2 may be
enforced by any court of competent jurisdiction, and the party seeking
enforcement shall be
entitled to an award of all costs, fees and expenses, including attorneys fees,
to be paid by the
party against whom enforcement is ordered.
 
    2.3    Assignment of Put Right. The Put Right granted in this Agreement may
only be
assigned by a Holder in connection with a permitted transfer of Series A Shares
by the Holder in
accordance with Clause 10 of the Purchase Agreement.
 
    2.4    Successors and Assigns. Except as otherwise provided herein, the
terms and
conditions of this Agreement shall inure to the benefit of and be binding upon
the respective
successors and assigns of the parties (including permitted transferees of any
Series A Shares).
Nothing in this Agreement, express or implied, is intended to confer upon any
party other than
the parties hereto or their respective successors and assigns any rights,
remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.
 
    2.5    Severability. In case any provision of this Agreement shall be
invalid, illegal, or
unenforceable, the validity, legality, and enforceability of the remaining
provisions shall not in
any way be affected or impaired thereby.
 
    2.6    Amendment and Waiver. Except as otherwise expressly provided, the
obligations
of WaferGen US and the rights of the Holders under this Agreement may be
amended, modified
or waived only with the written consent of WaferGen US and Holders holding at
least a majority
of all Series A Shares then held by all Holders (excluding for purposes of this
calculation any
Series A Shares held by WaferGen US or its nominee(s)).
 
    2.7    Delays or Omissions. It is agreed that no delay or omission to
exercise any right,
power, or remedy accruing to any Holder, upon any breach, default or
noncompliance of
WaferGen US under this Agreement, shall impair any such right, power, or remedy,
nor shall it
be construed to be a waiver of any such breach, default or noncompliance, or any
acquiescence
therein, or of any similar breach, default or noncompliance thereafter
occurring. It is further
agreed that any waiver, permit, consent, or approval of any kind or character on
any Holder’s
part of any breach, default or noncompliance under the Agreement or any waiver
on such
Holder’s part of any provisions or conditions of this Agreement must be in
writing and shall be
effective only to the extent specifically set forth in such writing. All
remedies, either under this
Agreement, by law, or otherwise afforded to Holders, shall be cumulative and not
alternative.
 
    2.8    Notices. All notices required or permitted hereunder shall be in
writing and shall
be deemed effectively given: (i) upon personal delivery to the party to be
notified, (ii) when sent
by confirmed telex or facsimile if sent during normal business hours of the
recipient; if not, then
 
3

--------------------------------------------------------------------------------

 
on the next business day, (iii) five (5) days after having been sent by
registered or certified mail,
return receipt requested, postage prepaid, or (iv) one (1) day after deposit
with a United States
recognized overnight courier, specifying next-day delivery, with written
verification of receipt.
All communications shall be sent to the party to be notified at the address as
set forth on the
signature pages hereof or at the current address of the Holder on the books and
records of the
Company or at such other address as such party may designate by ten (10) days’
advance written
notice to the other parties hereto. All notices sent to the Company or WaferGen
US shall also be
sent to: Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105,
Attention:
John M. Rafferty (Telecopier: (415) 268-7305).
 
    2.9    Attorneys’ Fees. In the event that any dispute among the parties to
this
Agreement should result in litigation, the prevailing party in such dispute
shall be entitled to
recover from the losing party all fees, costs and expenses of enforcing any
right of such
prevailing party under or with respect to this Agreement, including without
limitation, such
reasonable fees and expenses of attorneys and accountants, which shall include,
without
limitation, all fees, costs and expenses of appeals.
 
    2.10    Titles and Subtitles. The titles of the sections and subsections of
this Agreement
are for convenience of reference only and are not to be considered in construing
this Agreement.
 
    2.11    Counterparts. This Agreement may be executed in any number of
counterparts,
each of which shall be an original, but all of which together shall constitute
one instrument.
 
    2.12    Definitions. For purposes of this Agreement, the terms below shall
have the
definitions ascribed to them below:
 
        2.12.1    “Common Stock” means the common stock, par value $0.001 per
share,
               of WaferGen US.
 
        2.12.2    The “Exchange Price” shall be equal to USD $2.25 per share.
 
        2.12.3    “Exchange Securities” shall mean shares of Common Stock of
WaferGen
             US.
 
        2.12.4
 
    2.13    Certain Restrictions. Each Holder understands that any shares of
Common Stock
of WaferGen US to be received in an Exchange may be characterized as “restricted
securities”
under the federal securities laws inasmuch as they would be acquired from
WaferGen US in a
transaction not involving a public offering and that under such laws and
applicable regulations,
such securities may be resold without registration under the Securities Act of
1933, as amended
(the “Act”), only in certain limited circumstances. In this regard, the Holder
represents that it is
familiar with Rule 144 under the Act, as presently in effect, and understands
the resale
limitations imposed thereby and by the Act. The Holder understands that any
shares of Common
Stock of WaferGen US received in an Exchange have not been and will not be
registered under
the Act and have not been and will not be registered or qualified in any state
in which they are
offered, and thus the Holder will not be able to resell or otherwise transfer
any such shares of
Common Stock unless they are registered under the Act and registered or
qualified under
 
4

--------------------------------------------------------------------------------

 
applicable state securities laws, or an exemption from such registration or
qualification is
available.
 
    2.14    Transfer Taxes. All excise, transfer, stamp, documentary, filing,
recordation and
other similar taxes which may be imposed or assessed as the result of any
Exchange, together
with any interest, additions or penalties with respect thereto and any interest
in respect of such
additions or penalties, shall be borne equally by WaferGen US and the Holder
consummating
such Exchange.
 
 
 
 
5

--------------------------------------------------------------------------------

 
IN WITNESS WHEREOF, the parties hereto have executed this PUT OPTION AGREEMENT
as of the date set forth in the first paragraph hereof.

WAFERGEN US:

WAFERGEN BIO-SYSTEMS, INC.

 
 By: /s/ Alnoor Shivji
     
 Alnoor Shivji
     
 Chairman, President & Chief Executive Officer
   

Address:
WaferGen Bio-systems, Inc.
Bayside Technology Center
46531 Fremont Blvd.
Fremont, CA 94538, USA
Facsimile: 510 651 4599

WAFERGEN MALAYSIAN INVESTOR:

MALAYSIAN TECHNOLOGY DEVELOPMENT CORPORATION SDN BHD

 
 By: /s/ Dato' Azlin b. Alias
     
 Dato' Azlin b. Alias
           

Address:
Level 8-9, Menara Yayasan Tun Razak,
Jalan Bukit Bintang,
55100 Kuala Lumpur
Facsimile: 03-2163 7570

6

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------